Abstract
Background
Osteonectin has been suggested to be important in the progression of pancreatic cancer but has not been correlated with survival. We determined the osteonectin expression and its influence on survival in patients with ampullary carcinoma.
Methods
Tissue microarrays were constructed from the tumors of 56 patients with ampullary cancer undergoing pancreaticoduodenectomy. Immunohistochemical staining for osteonectin was undertaken and compared with staining in chronic pancreatitis (n = 13) and normal pancreas (n = 19). Survival curves were created by the Kaplan-Meier method and compared by log rank analysis. Median follow-up for all living patients with ampullary cancer was 69.6 months.
Results
Osteonectin was significantly (P < .05, Fisher’s exact test) overexpressed in the stroma of ampullary cancers (90%) relative to chronic pancreatitis (62%) and normal pancreas (0%). Tumors expressing osteonectin were more likely to have nodal metastases than those lacking osteonectin expression (48% vs. 0%, P = .06, Fisher’s exact test) and showed decreased survival. Node-negative status, pylorus preservation at the time of pancreaticoduodenectomy, and lack of osteonectin expression were predictors of prolonged survival by multivariate analysis.
Conclusions
Although the importance of tumor-stroma interactions in periampullary cancers is not fully understood, our data suggest that osteonectin is an integral stromal element in ampullary cancers, and its overexpression is associated with decreased survival.
Similar content being viewed by others
References
Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107:1055–61
Kyriakides TR, Bornstein P. Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 2003; 90:986–92
Sodek J, Zhu B, Huynh MH, Brown TJ, Ringuette M. Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res 2002; 43:308–19
Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000; 19:615–22
Kolb A, Kleeff J, Guweidhi A, et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther 2005; 4:740–6
Fukui R, Nishimori H, Hata F, et al. Metastases-related genes in the classification of liver and peritoneal metastasis in human gastric cancer. J Surg Res 2005; 129:94–100
Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23:3526–35
Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006; 118:2255–61
Celetti A, Testa D, Staibano S, et al. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 2005; 11:8019–27
Donati V, Boldrini L, Dell’Omodarme M, et al. Osteopontin expression and prognostic significance in non–small cell lung cancer. Clin Cancer Res 2005; 11:6459–65
Van Heek NT, Maitra A, Koopmann J, et al. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther 2004; 3:651–6
Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107:1049–54
Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004; 92:679–90
Rich JN, Shi Q, Hjelmeland M, et al. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003; 278:15951–7
Ledda MF, Adris S, Bravo AI, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997; 3:171–6
Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 2001; 61:1833–8
Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003; 22:5021–30
Guweidhi A, Kleeff J, Adwan H, et al. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 2005; 242:224–34
Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 2005; 29:359–67
Zhou H, Schaefer N, Wolff M, Fischer HP. Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 2004; 28:875–82
Matsubayashi H, Watanabe H, Yamaguchi T, et al. Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of Vater. Cancer 1999; 86:596–607
AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002
De Lott LB, Morrison C, Suster S, Cohn DE, Frankel WL. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med 2005; 129:1100–5
Yokoyama N, Shirai Y, Wakai T, Nagakura S, Akazawa K, Hatakeyama K. Jaundice at presentation heralds advanced disease and poor prognosis in patients with ampullary carcinoma. World J Surg 2005; 29:519–23
Brown KM, Tompkins AJ, Yong S, Aranha GV, Shoup M. Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg 2005; 140:529–32;discussion 532–3
Di Giorgio A, Alfieri S, Rotondi F, et al. Pancreatoduodenectomy for tumors of Vater’s ampulla: report on 94 consecutive patients. World J Surg 2005; 29:513–8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bloomston, M., Ellison, E.C., Muscarella, P. et al. Stromal Osteonectin Overexpression Is Associated with Poor Outcome in Patients with Ampullary Cancer. Ann Surg Oncol 14, 211–217 (2007). https://doi.org/10.1245/s10434-006-9128-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-006-9128-3